EU Servier Court Ruling 'Reduces Competition Law Risks For Pharma'
Executive Summary
The EU’s General Court judgement in the Servier pay-for-delay case will put more pressure on competition authorities to show evidence of alleged abuse of a dominant position.
You may also be interested in...
Top EU Court Urged To Take Harder Line On Servier Perindopril Agreements
European allegations of abuses of dominant positions in the pharmaceutical sector may once again be reframed, after the CJEU was advised by advocate general Juliane Kokott to set aside certain findings of the General Court on settlement deals made by Servier with multiple generics firms over perindopril.
CJEU Urged To Take Harder Line On Servier Perindopril Agreements
European allegations of abuses of dominant positions in the pharmaceutical sector may once again be reframed, after the CJEU was advised by advocate general Juliane Kokott to set aside certain findings of the General Court on settlement deals made by Servier with multiple generics firms over perindopril.
EU Investigates Teva For Undermining Copaxone Generics
The European Commission is investigating whether Teva “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.